Isolating peripheral blood mononuclear cells (PBMCs) and plasma is the starting point for nearly every modern immunology breakthrough —immunotherapy, cell therapy, liquid biopsy, and immunodiagnostics —a ~$500B combined market. Yet the 50-year-old manual workflow takes 3–4 hours, is subjective, centralized, and biohazardous. Aridica Corporation replaces it with a single push of a button that delivers both PBMCs and plasma in 30 minutes—novice-friendly, decentralized, consistent, safely and eco-friendly.